98%
921
2 minutes
20
Objective: To evaluate the effects of controlled ovarian hyperstimulation (COH) treatment on cardiac functions using tissue Doppler imaging (TDI).
Study Design: Twenty-one patients aged 22-35 years were enrolled to COH cycles. Each subject underwent a conventional transthoracic echocardiographic examination that included an assessment of cardiac function. Measurements were taken twice--the first on the second day of the cycle and the second on the day when human chorionic gonadotropin was administered. Twenty-one healthy women were chosen for the control group.
Results: The COH treatment did not cause favorable cardiac function changes. The parameters showing the left ventricular diastolic function such as early diastolic peak flow velocity (E), late diastolic peak flow velocity (A), mitral E/A ratios, mitral E wave, deceleration time (DT), lateral isovolumic relaxation time (IVRT), and left ventricular myocardial performance index (LVMPI) were not changed. The COH treatment did not affect the right ventricular diastolic functions such as tricuspid valve E wave, DT, right ventricular (RV) IVRT, or right ventricular myocardial performance index (RVMPI). Concurrently, the COH treatment showed no effects on the right and left ventricular systolic functions.
Conclusion: TDI findings reveal no effects of the COH treatment on cardiac function.
Download full-text PDF |
Source |
---|
J Immunother Cancer
September 2025
Division of Hematology & Oncology, Department of Medicine, School of Medicine, University of California, Irvine, California, USA
Background: γδ T cells possess unique immunological features including tissue tropism, major histocompatibility complex-independent antigen recognition, and hybrid T/natural killer cell properties that make them promising candidates for cancer immunotherapy. However, the therapeutic potential of Vδ1 γδ T cells, particularly when engineered with chimeric antigen receptors (CARs), remains underexplored in solid tumors such as pancreatic cancer (PC), largely due to their low abundance in peripheral blood and challenges in ex vivo expansion. This study aims to directly compare the preclinical safety and efficacy among CAR-engineered Vδ1 γδ T cells, Vδ2 γδ T cells, and conventional αβ T cells.
View Article and Find Full Text PDFChest
September 2025
Case Western Reserve University, Cleveland, OH; University Hospitals, Cleveland, OH.
Background: Broad genomic testing is necessary to treat stage IV non-small cell lung cancer (NSCLC) patients. We describe a NSCLC precision medicine service at an academic-community practice and provide model-based estimates of the impact of a similar intervention.
Research Question: Will implementation of a precision medicine service increase NSCLC next-generation sequencing (NGS) rates, improve testing turnaround times (TAT), and increase rates of actionable genomic alterations (AGAs)?
Study Design And Methods: PREDICT (PREcision meDICine Thoracic) consisted of: 1) system-wide reflex testing of stage IV NSCLC patients by in-house solid tumor NGS focused assay and PD-L1 testing, 2) navigator, 3) molecular tumor board (MTB), 4) integrated information portal (OncoTracker) for real-time updates on samples processing, results, and treatment recommendations by the MTB.
Curr Treat Options Oncol
September 2025
Division of Gynecologic Oncology, Department of Surgery, City of Hope National Medical Center, Duarte, CA, USA.
Ovarian cancer, particularly high-grade serous carcinoma (HGSC), remains a leading cause of mortality in gynecologic oncology. Emerging research identifies serous tubal intraepithelial carcinoma (STIC) as a precursor lesion in many HGSC cases, highlighting its role in ovarian cancer pathogenesis and prevention. Management of STIC is challenging, as there is only limited data available to guide clinical decision-making.
View Article and Find Full Text PDFESMO Open
September 2025
UPMC Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, USA.
Background: All three cyclin-dependent kinase 4/6 inhibitors (CDK4/6i; palbociclib, ribociclib, and abemaciclib) plus aromatase inhibitor (AI) significantly prolonged progression-free survival (PFS) versus placebo plus AI and achieved a similar reduction in risk of disease progression in randomized controlled trials (RCTs) evaluating first-line (1L) treatment of hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (mBC). To date, there have been no head-to-head RCT data comparing CDK4/6i, and most real-world comparative effectiveness studies were limited by small sample sizes and/or short follow-up. In this analysis, we compared real-world PFS (rwPFS) in patients with HR-positive/HER2-negative mBC receiving 1L CDK4/6i plus AI in United States routine clinical practice.
View Article and Find Full Text PDFInt J Environ Res Public Health
August 2025
National Institute of Public Health, University of Southern Denmark, Studiestræde 6, DK-1455 Copenhagen, Denmark.
The aim of this paper was to evaluate health, psychological distress, and functioning during the COVID-19 pandemic among Danish adults with and without a history of mental illness. Data were drawn from three online surveys conducted in May 2020 (n = 3134), January 2021 (n = 1170), and January 2022 (n = 1174) as part of the Danish contribution to the Collaborative Outcomes study on Health and Functioning during Infection Times (COH-FIT). The prevalence of mental and physical health issues, psychological distress (stress, sleep problems, loneliness, and boredom) and levels of functioning (self-care, interpersonal relationships, hobbies/leisure, and work/education) were evaluated at four different time points stratified by history of mental illness.
View Article and Find Full Text PDF